TeamDrive
RUS

NovaMedica

www.novamedica.com

NovaMedica is a modern Russian pharmaceutical company established in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceutical products and technologies as well as at development and implementation of own R&D-projects.

NovaMedica owns intellectual property rights within Russia and the CIS for 36 innovations which are part of the portfolio of RusnanoMedInvest, venture capital foundation. These are drugs for antivirus and anti-inflammatory therapy, to cure ophthalmic diseases and epilepsy as well as innovative technologies to detect oncological and infectious diseases.

NovaMedica also develops a pipeline of its own drug products. R&D Division of the company plans to develop about 15 own drugs by 2022. Five out of them are already on the different stage of development – from creation of a drug formulation up to clinical trials and state registration, and four more are on the stage of launch. These are drugs to cure disease in the sphere of gastroenterology, pain treatment, neurology, ophthalmology and rheumatology.

In April 2017 NovaMedica launched the Technology Center with state-of-the-art technological capabilities which were previously unobtainable in the Russian pharmaceutical industry.

In 2016 NovaMedica became the key partner of Pfizer in Russia. Within the frameworks of this partnership NovaMedica stared construction of a pharmaceutical GMP-facility in the Kaluga region in May 2017. 

NovaMedica possesses a well-developed infrastructure to market promotion and selling of pharmaceutical products. 

Media Center

  • 20 July 2018

    Russian drugs with precise delivery system may become available in five years

    A system of intracellular drug delivery was developed at the Institute of Theoretical and Experimental Biophysics (ITEB) of The Russian Academy of Sciences (RAS). This principle is expected to be used to obtain highly effective anti-inflammatory drugs.

  • 19 July 2018

    China will bring down prices for cancer drugs

    China’s state medical insurance administration will start a new round of negotiations with pharmaceutical companies to add more cancer drugs to the insurance list.

  • 18 July 2018

    Russia and Bulgaria signed cooperation agreement

    Last week, on July 10, 2018, in Sofia Vladislav Shestakov – Director of the State Institute of Drugs and Good Practices, Deputy Head of the State GMP Inspectorate met with Professor Assena Stoimenova, Executive Director of the Bulgarian Drug Agency (Medicines Agency of the Bulgarian Health Ministry).

  • 18 July 2018

    EMA Relocation Countdown: Some Industry Viewpoints

    July 1, 2018 marked the start of the six-month countdown to the European Medicines Agency (EMA) relocation of its operations to Amsterdam. Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry.

Read more